地拉罗司什么人适合用？

(Enrig) is an iron chelator product developed by the Swiss pharmaceutical company Novartis. It is the first oral iron anthelmintic approved by the US FDA for routine use. So, who is suitable for deferasirox (Enrig)?

Indications for Deferasirox (Enrige):

1. Patients with chronic iron overload transfusion hemosiderinosis secondary to blood transfusion who are 2 years old or older will develop symptoms of chronic iron overload when serum ferritin continues to be >1000 L. At this time, iron chelation therapy should be started. 2. Iron chelators can also be given to patients undergoing ASCT when iron overload occurs. 3. It can be used to treat reversible renal insufficiency caused by Fanconi syndrome.

In addition, in Europe, deferasirox is recommended as a first-line drug for thalassemia iron overload patients over 6 years old, and clinical studies are currently underway in China. Phase II and III clinical trials and pharmacokinetic studies have shown that deferasirox has good safety and tolerability, can significantly reduce iron load in the heart and liver, and is easily accepted by patients.

At the same time, Deferasirox (Enrige) also has pharmacological properties such as antifungal (such as Mucor that grows in an iron-rich environment), anti-cell proliferation, anti-malarial, anti-oxidative stress damage, anti-cytotoxic-induced apoptosis, etc.; it can be used for the treatment of secondary hemochromatosis, porphyria cutanea tarda and other diseases. There is no unified answer to the question of how many courses of treatment Deferasirox (Enrige) should generally take, because each patient's condition and physical condition are different. Some patients have better physical constitution and milder conditions. Deferasirox is easier to work in the patient's body and heals faster. Generally, one or two courses of treatment are enough, while patients with poor physical fitness or severe illness need to use it for a longer period of time to be effective. The specific duration of taking the medicine depends on the patient's medication. 

The above are the indications of (ENRIG) provided by our Medical Companion Travel Overseas Medical Consulting Service Company.

Related hot article recommendations: